Announcements
27 March 2024
Prof. Dr. Matthias May Appointed Section Editor-in-Chief of Section “Genitourinary Oncology” in Current Oncology
We are pleased to announce that Prof. Dr. Matthias May has been appointed Section Editor-in-Chief of the Section “Genitourinary Oncology” in Current Oncology (ISSN: 1718-7729). Prof. Dr. Matthias May, born in Berlin (Germany), is a Professor of Urology at St. Elisabeth Hospital Straubing (Bavaria, Germany). Additionally, he holds a teaching position at the Department of Urology, University of Regensburg (Bavaria, Germany). His primary professional focus is operative urologic oncology surgery, including robot-assisted procedures. He maintains a broad scientific interest in urology, particularly in developing prognostic prediction models (including biomarker-based) for various urologic cancers across diverse clinical settings. In recent years, his research has increasingly focused on translational projects involving penile, prostate, and bladder cancer. Prof. Dr. May has secured multiple grants for his research endeavors and has initiated/founded more than 30 multicenter studies. He has authored over 250 peer-reviewed articles, serving as the first or senior author for most of them. Presently, his h-index stands at 39, with 5,802 citations to his work (i10-index: 137).
The following is a short Q&A with Prof. Dr. Matthias May, who has shared his vision for the journal's advancement and impact, the promising future of genitourinary oncology research, and his positive view on the development of open access in the publishing field:
1. What appealed to you about the journal that made you want to take the role of its Section Editor-in-Chief?
Current Oncology has always stood out to me as a beacon of excellence and innovation in the landscape of medical research publishing. Its long-standing tradition of fostering rigorous scientific inquiry and disseminating cutting-edge findings in oncology resonated deeply with my professional ethos and aspirations. Serving as the Section Editor-in-Chief for “Genitourinary Oncology” is not just an honor; it represents a unique opportunity to contribute to the advancement of a field that is at the cusp of transformative breakthroughs. I was particularly drawn to the journal's commitment to integrity, inclusivity, and the promotion of multidisciplinary collaboration, which aligns perfectly with my vision of pushing the boundaries of genitourinary oncology research.
2. What is your vision for the journal?
My vision for Current Oncology is its elevation to unprecedented levels of influence and innovation in the field of genitourinary oncology. In my role, I aim to champion the integration of multidisciplinary research approaches, bridging the gap between basic science, clinical research, and patient care. By doing so, we can provide a holistic perspective on the complexities of cancer diagnosis and treatment, fostering innovations that are both scientifically profound and clinically applicable. Furthermore, I am committed to enhancing the journal's accessibility and global reach, ensuring that cutting-edge research is available to a wide audience, thereby accelerating the translation of research discoveries into clinical practice.
3. What does the future of this field of genitourinary oncology look like?
The future of genitourinary (GU) oncology is incredibly promising, marked by rapid advancements in precision and interventional medicine, as well as personalized treatment plans. We are on the cusp of a paradigm shift where molecular genetics and biomarker research will significantly enhance our understanding of GU cancers and improve their treatment. Furthermore, the integration of artificial intelligence and machine learning in diagnostics and treatment planning holds tremendous potential to revolutionize patient care. As these technologies evolve, we will see a more tailored approach to oncology, prioritizing the patient’s and tumor’s unique genetic profile, patient lifestyle, and quality of life, as well as treatment preferences. In the coming years, I anticipate a more collaborative and interdisciplinary approach to research, driving innovations that will substantially improve outcomes for patients with GU cancers.
4. What do you think of the development of open access in the publishing field?
The development of open access in the publishing field is a transformative movement that democratizes knowledge and accelerates scientific discovery. By making research findings freely available, open access enhances the visibility and impact of scholarly work, facilitating greater collaboration and innovation across disciplines. This model encourages a more inclusive scholarly community, where valuable insights are not hidden behind paywalls, but shared widely, contributing to the collective advancement of science. While there are challenges to navigate, particularly regarding sustainable funding models and ensuring the quality of published work, the benefits of open access in fostering a more informed and engaged global research community are undeniable. As Section Editor-in-Chief, I am committed to supporting and advancing open access initiatives, recognizing their critical role in the future of academic publishing.
We wish Prof. Dr. Matthias May every success in his position as Section Editor-in-Chief, and we look forward to his future contributions to the journal.
